United States (US) Non-alcoholic Steatohepatitis Market (2025-2031) | Size & Revenue, Value, Trends, Competitive Landscape, Outlook, Segmentation, Companies, Growth, Share, Forecast, Industry, Analysis

2.1 Key Highlights of the Report

2.2 Report Description

2.3 Market Scope & Segmentation

2.4 Research Methodology

2.5 Assumptions

3.1 United States (US) Country Macro Economic Indicators

3.2 United States (US) Non-alcoholic Steatohepatitis Market Revenues & Volume, 2021 & 2031F

3.3 United States (US) Non-alcoholic Steatohepatitis Market - Industry Life Cycle

3.4 United States (US) Non-alcoholic Steatohepatitis Market - Porter's Five Forces

3.5 United States (US) Non-alcoholic Steatohepatitis Market Revenues & Volume Share, By Drug Type, 2021 & 2031F

3.6 United States (US) Non-alcoholic Steatohepatitis Market Revenues & Volume Share, By Sales Channel, 2021 & 2031F

3.7 United States (US) Non-alcoholic Steatohepatitis Market Revenues & Volume Share, By Disease Cause, 2021 & 2031F

3.8 United States (US) Non-alcoholic Steatohepatitis Market Revenues & Volume Share, By End User, 2021 & 2031F

4.1 Impact Analysis

4.2 Market Drivers

4.2.1 Increasing prevalence of obesity and metabolic syndrome in the US population, leading to a higher incidence of non-alcoholic steatohepatitis (NASH).

4.2.2 Growing awareness among healthcare providers and patients about the risks and consequences of NASH, driving early diagnosis and treatment.

4.2.3 Advances in diagnostic technologies and treatment options for NASH, improving patient outcomes and increasing demand for related products and services.

4.3 Market Restraints

4.3.1 Limited availability of approved pharmacological treatments for NASH, leading to challenges in effectively managing the disease.

4.3.2 High costs associated with NASH diagnostics and treatments, potentially limiting access for some patient populations.

4.3.3 Regulatory hurdles and uncertainties surrounding drug approval processes for NASH therapies, impacting market growth and investment.

6.1 United States (US) Non-alcoholic Steatohepatitis Market, By Drug Type

6.1.1 Overview and Analysis

6.1.2 United States (US) Non-alcoholic Steatohepatitis Market Revenues & Volume, By Drug Type, 2021- 2031F

6.1.3 United States (US) Non-alcoholic Steatohepatitis Market Revenues & Volume, By Vitamin E and Pioglitazone, 2021- 2031F

6.1.4 United States (US) Non-alcoholic Steatohepatitis Market Revenues & Volume, By Ocaliva, 2021- 2031F

6.1.5 United States (US) Non-alcoholic Steatohepatitis Market Revenues & Volume, By Elafibranor, 2021- 2031F

6.1.6 United States (US) Non-alcoholic Steatohepatitis Market Revenues & Volume, By Selonsertib and Cenicriviroc, 2021- 2031F

6.1.7 United States (US) Non-alcoholic Steatohepatitis Market Revenues & Volume, By Obeticholic Acid, 2021- 2031F

6.1.8 United States (US) Non-alcoholic Steatohepatitis Market Revenues & Volume, By Others, 2021- 2031F

6.2 United States (US) Non-alcoholic Steatohepatitis Market, By Sales Channel

6.2.1 Overview and Analysis

6.2.2 United States (US) Non-alcoholic Steatohepatitis Market Revenues & Volume, By Hospital Pharmacy, 2021- 2031F

6.2.3 United States (US) Non-alcoholic Steatohepatitis Market Revenues & Volume, By Online Providers, 2021- 2031F

6.2.4 United States (US) Non-alcoholic Steatohepatitis Market Revenues & Volume, By Retail Pharmacy, 2021- 2031F

6.3 United States (US) Non-alcoholic Steatohepatitis Market, By Disease Cause

6.3.1 Overview and Analysis

6.3.2 United States (US) Non-alcoholic Steatohepatitis Market Revenues & Volume, By Hypertension, 2021- 2031F

6.3.3 United States (US) Non-alcoholic Steatohepatitis Market Revenues & Volume, By Heart Disease, 2021- 2031F

6.3.4 United States (US) Non-alcoholic Steatohepatitis Market Revenues & Volume, By High Blood Lipid, 2021- 2031F

6.3.5 United States (US) Non-alcoholic Steatohepatitis Market Revenues & Volume, By Type 2 Diabetes, 2021- 2031F

6.3.6 United States (US) Non-alcoholic Steatohepatitis Market Revenues & Volume, By Obesity, 2021- 2031F

6.4 United States (US) Non-alcoholic Steatohepatitis Market, By End User

6.4.1 Overview and Analysis

6.4.2 United States (US) Non-alcoholic Steatohepatitis Market Revenues & Volume, By Hospitals, 2021- 2031F

6.4.3 United States (US) Non-alcoholic Steatohepatitis Market Revenues & Volume, By Clinics, 2021- 2031F

6.4.4 United States (US) Non-alcoholic Steatohepatitis Market Revenues & Volume, By Homecare settings, 2021- 2031F

7.1 United States (US) Non-alcoholic Steatohepatitis Market Export to Major Countries

7.2 United States (US) Non-alcoholic Steatohepatitis Market Imports from Major Countries

8.1 Average time to diagnosis of NASH in the US population.

8.2 Percentage of NASH patients receiving guideline-recommended treatment.

8.3 Adoption rate of non-invasive diagnostic tools for NASH assessment.

8.4 Patient adherence rates to NASH treatment regimens.

8.5 Number of ongoing clinical trials for NASH therapies in the US market.

9.1 United States (US) Non-alcoholic Steatohepatitis Market Opportunity Assessment, By Drug Type, 2021 & 2031F

9.2 United States (US) Non-alcoholic Steatohepatitis Market Opportunity Assessment, By Sales Channel, 2021 & 2031F

9.3 United States (US) Non-alcoholic Steatohepatitis Market Opportunity Assessment, By Disease Cause, 2021 & 2031F

9.4 United States (US) Non-alcoholic Steatohepatitis Market Opportunity Assessment, By End User, 2021 & 2031F

10.1 United States (US) Non-alcoholic Steatohepatitis Market Revenue Share, By Companies, 2024

10.2 United States (US) Non-alcoholic Steatohepatitis Market Competitive Benchmarking, By Operating and Technical Parameters